

GENEREX BIOTECHNOLOGY CORP
Form 8-K
October 14, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 14, 2009

GENEREX BIOTECHNOLOGY CORPORATION
(Exact name of registrant as specified in its charter)

| | | |
|--|--|--|
| Delaware (State or other jurisdiction of incorporation) | 000-29169 (Commission File Number) | 98-0178636 (I.R.S Employer Identification No.) |
|--|--|--|

| | |
|--|-----------------------|
| 33 Harbour Square, Suite 202, Toronto, Ontario Canada (Address of principal executive offices) | M5J 2G2 (Zip Code) |
|--|-----------------------|

Registrant's telephone number, including area code: (416) 364-2551

N/A
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On October 14, 2009, Genex Biotechnology Corporation (the “Company”) announced the details for accessing a conference call, scheduled for Thursday, October 15, 2009 at 11:00 a.m. Eastern Daylight Time, to update the investment community on the Company’s flagship product, Genex Oral-lyn™ and other corporate activities. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit Number | Description |
|-------------------|---|
| 99.1 | Press release issued by Genex Biotechnology Corporation dated October 14, 2009 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENEREX BIOTECHNOLOGY
CORPORATION.

Date: October 14, 2009

/s/ Rose C. Perri
Chief Operating Officer and Chief
Financial Officer
(principal financial officer)

EXHIBIT INDEX

| Exhibit Number | Description |
|-------------------|---|
| 99.1 | Press release issued by Generex Biotechnology Corporation dated October 14, 2009 |
